BMJ:慢性病与肿瘤发生及死亡风险增加

2018-02-02 zhangfan MedSci原创

研究认为慢性病是被严重忽略的肿瘤风险因素,而体力活动可大大降低慢性病患者的肿瘤风险

近日来自台湾的研究人员考察了主要慢性病和疾病标志物与癌症风险的独立和联合相关性,并考察了体力活动和体育运动对减少与慢性病和疾病标志物相关的癌症风险的效果。

405878名参与者进行了心血管疾病(血压、总胆固醇和心率)、糖尿病、慢性肾病标志物(蛋白尿与肾小球滤过率)、肺病以及痛风性关节炎标志物(尿酸)检查,平均随访8.7年。通过慢性疾病风险评分衡量疾病程度,研究的主要终点是肿瘤发生率以及死亡率。

研究发现,除血压与肺病之外,其余的疾病或标志物与肿瘤风险显著相关,调整后的风险比范围1.07-1.44。所有疾病及标志物与肿瘤死亡风险增加相关,其调整后的风险比范围1.12-1.70。研究人员通过慢性疾病风险评分发现疾病及标志物剂量-反应方程式与癌症风险呈正相关:最高得分导致肿瘤发生和死亡风险分别增加2.21倍和4.00倍。慢性疾病风险评分升高导致患者生存期缩短,最多导致男性寿命缩短13.3年,女性寿命缩短15.9年。慢性疾病对患者肿瘤发生率及死亡率的效应与5种主要生活方式对肿瘤发生和死亡的影响相近(发生率 20.5% vs 24.8%;死亡率38.9% vs 39.7%)。体力活力或体育锻炼人群,慢性病导致的肿瘤发生和死亡风险分别降低48%和27%。

研究认为慢性病是被严重忽略的肿瘤风险因素,而体力活动可大大降低慢性病患者的肿瘤风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848448, encodeId=e29918484489f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 27 06:24:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285502, encodeId=b54128550200, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 06 00:18:37 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285191, encodeId=1b70285191cb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 05 00:28:42 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255727, encodeId=51f51255e2785, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264039, encodeId=10901264039db, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-08-27 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848448, encodeId=e29918484489f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 27 06:24:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285502, encodeId=b54128550200, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 06 00:18:37 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285191, encodeId=1b70285191cb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 05 00:28:42 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255727, encodeId=51f51255e2785, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264039, encodeId=10901264039db, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-06 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1848448, encodeId=e29918484489f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 27 06:24:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285502, encodeId=b54128550200, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 06 00:18:37 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285191, encodeId=1b70285191cb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 05 00:28:42 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255727, encodeId=51f51255e2785, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264039, encodeId=10901264039db, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-05 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1848448, encodeId=e29918484489f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 27 06:24:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285502, encodeId=b54128550200, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 06 00:18:37 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285191, encodeId=1b70285191cb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 05 00:28:42 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255727, encodeId=51f51255e2785, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264039, encodeId=10901264039db, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848448, encodeId=e29918484489f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 27 06:24:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285502, encodeId=b54128550200, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 06 00:18:37 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285191, encodeId=1b70285191cb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 05 00:28:42 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255727, encodeId=51f51255e2785, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264039, encodeId=10901264039db, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sun Feb 04 00:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-04 qjddjq

相关资讯

国家卫计委公布慢性病综合防控示范区建设评估结果

12月19日,国家卫计委公布了第一批国家慢性病综合防控示范区建设复审结果。

宁波家庭医生配慢性病处方药 药量可增至3个月

自2017年12月起,宁波将进一步完善实施基层医疗机构慢性病门诊用药管理新办法。

杭州可给慢病患者开12周药

近日,浙江省杭州市人力资源和社会保障局、卫生计生委、商务委、市场监管局4部门印发了关于做好慢性病门诊管理服务工作有关事项的通知,调整了医保门诊管理政策。通知规定,自12月1日起,杭州市患有特定慢性病的签约病人一次可开出4周至12周的慢性病长期处方。

中国研究称:控制这六个因素,至2030年可避免260多万人死于慢性病

20世纪90年代以来,随着中国经济发展、医疗技术和服务提升以及各项全民干预措施逐步实施,中国居民的主要慢性病死亡和期望寿命得到了大幅改善。

浙江七举措推进慢性病防控

浙江省政府办公厅近日发布《浙江省防治慢性病中长期规划(2017-2025年)》,提出到2020年和2025年,居民重点慢性病核心知识知晓率分别达到60%和70%。

JAMA:激素治疗用于绝经后女性慢性病一级预防:USPSTF推荐声明

2017年12月,美国预防服务工作组(USPSTF)在《JAMA》发布了激素治疗用于绝经后女性慢性病一级预防的推荐声明。